A ngiotensin (Ang) II exerts its important physiological functions through 2 distinct receptor subtypes, the type 1 (AT 1 ) and type 2 (AT 2 ) receptors. 1 The AT 1 receptor is expressed in diverse adult tissues, and its distribution is indicative of the fundamental role of Ang II on the regulation of cardiovascular and renal homeostasis. The predominant actions of Ang II, such as vasoconstriction, cellular proliferation and growth, renal sodium retention, and release of aldosterone, are linked to the activation of various signal-transduction pathways modulated by the AT 1 receptor. Although the AT 2 receptor is highly expressed in the fetus, its expression in adult tissues is low but increases in response to injury. [2] [3] [4] [5] It has been demonstrated that AT 1 and AT 2 receptors have counterregulatory interactions in the cardiovascular system. 2 The AT 2 receptor has been shown to exert an inhibitory effect on the growth-promoting action of the AT 1 receptor. 6 The cross-talk between AT 1 and AT 2 receptors has also been suggested to participate in the regulation of blood pressure. Ang II binding to the AT 1 receptor activates G proteincoupled phospholipase C and inositol-1,4,5-triphosphate, which increases intracellular Ca 2ϩ levels resulting in vasoconstriction. On the other hand, Ang II binding to the AT 2 receptor activates a counterregulatory pathway to induce vasorelaxation via activation of the kinin/NO/cGMP system. 4, 5 Indeed, it has been demonstrated that stimulation of the AT 2 receptor induces vasorelaxation in mesenteric, uterine, renal, coronary, and cerebral resistance vessels, as well as in large conduit vessels. 3-5 AT 2 receptor null mice manifest slightly higher blood pressures at baseline than wild-type mice and enhanced acute blood pressure responses to lowdose Ang II infusion. 7 In mice overexpressing AT 2 receptors, the pressor response to Ang II infusion is significantly attenuated but is restored after blockade of AT 2 receptors and/or blockade of NO synthase. 8 Based on these studies, it has been proposed that AT 2 receptor-mediated vasorelaxation may partly counteract AT 1 receptor-mediated vasoconstriction and thereby contribute to the antihypertensive and/or vasoprotective effects of AT 1 receptor blockers.
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Recent studies suggest that the upregulation of AT 2 receptor expression and associated vasorelaxation may play an important role in vascular remodeling. Consistent with this notion, the study by Savoia et al 9 in this issue of Hypertension provides exciting data demonstrating that small peripheral resistance arteries from hypertensive diabetic patients receiving long-term treatment with the AT 1 receptor blocker valsartan exhibited enhanced AT 2 receptor expression. This effect may be independent of blood pressure reduction, because AT 2 receptor expression was not changed in the atenolol-treated patients with similar blood pressure control.
Savoia et al 9 demonstrated that, in human resistance vessels, AT 2 receptors are not only present but functional. Indeed, AT 2 receptor activation was unmasked in resistance vessels of valsartan-treated patients in which, when AT 1 receptors were blocked, exogenous Ang II-induced vasorelaxation was blunted by the AT 2 receptor blocker PD123319. However, in the resistance vessels from these AT 1 receptor blockertreated patients, the Ang II-mediated vasorelaxation was only 7.5%. This modest vasodilatory effect suggests that the role of the AT 2 receptor in reducing blood pressure may be minimal, if at all. In the patients studied by Savoia et al, 9 upregulation of AT 2 receptors in the setting of AT 1 receptor blockade was associated with an improvement in resistance artery remodeling that was independent of blood pressure effects. Thus, these results suggest that the AT 2 receptor may play a significant role in vascular remodeling. AT 2 receptors have been shown to be upregulated under conditions associated with cardiovascular tissue injury, such as common carotid balloon injury, myocardial infarction, heart failure, and hypertension. 1, 4, 5 In the model of carotid balloon injury, treatment with valsartan significantly reduced intimal hyperplasia and concomitantly increased intimal, and to a lesser extent medial, AT 2 receptor expression in the injured vessel but not in the contralateral normal vessel. 4 These studies suggest that injury, as well as increased levels of Ang II associated with AT 1 receptor blockade, is required for the upregulation of AT 2 receptors in adult animals ( Figure) .
Despite normalization of blood pressure and reasonable, although not perfect, control of glycemia, the diabetic patients studied by Savoia et al 9 exhibited upregulation of the AT 2 receptor in resistance vessels after 1 year of treatment with valsartan. 9 What could have been the ongoing injury maintaining increased AT 2 receptor expression: genetic predisposition to vascular injury or phenotypic changes in the vasculature that occurred during the time that the patients were hypertensive and/or hyperglycemic and that could not be reversed by the antihypertensive therapy over a period of a year? These are questions, among others, that need to be addressed by future research.
Ang II, via the AT 1 receptor, has been demonstrated to increase reactive oxygen species production in the vessel wall through activation of reduced nicotinamide-adenine dinucleotide/reduced nicotinamide-adenine dinucleotide phosphate oxidase. 10 AT 1 receptor activation by Ang II stimulates inflammatory, fibrotic, and thrombotic processes, which contribute to Ang II-mediated inflammation and atherogenesis. 11, 12 Experimental and clinical studies using angiotensinconverting enzyme inhibitors and AT 1 receptor blockers have provided indirect evidence supporting the role of oxidative stress in the pathogenesis of endothelial dysfunction and atherogenesis. These latter studies also suggested that the role of oxidative stress in hypertensive vascular injury is in addition to, but independent of, the hemodynamic stress of blood pressure. [12] [13] [14] [15] The AT 1 receptor-mediated increase in vascular reactive oxygen species production leads to a decrease in the bioavailability of NO. Stimulation of AT 2 receptor increases NO production. An intriguing emerging notion is that the crosstalk between AT 1 and AT 2 receptors may play an important role in the maintenance of cardiovascular homeostasis in humans. The study by Savoia et al 9 implies that further elucidation of the interactions between the AT 1 and AT 2 receptors may provide us with a better understanding of the global role of Ang II in cardiovascular diseases.
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